News about "Novartis"

Novartis, SciNeuro Sign USD 1.7 Billion Licensing Deal to Develop Alzheimer's Therapies

Novartis has entered into an exclusive global licensing and collaboration agreement with SciNeuro Pharmaceuticals to develop and commercialize novel therapies for Alzheimer’s disease, in a deal valued at up to USD 1.7 billion.

Novartis | 13/01/2026 | By Darshana

Novartis to Add Fourth US Radioligand Therapy Plant in Florida

Novartis will expand its US radioligand therapy manufacturing network with a new purpose-built facility in Winter Park, Florida, strengthening patient access across the southeastern US and supporting the company’s broader USD 23 billion investment in advanced manufacturing and oncology innovation.

Novartis | 12/01/2026 | By News Bureau

Sanofi and Novartis Reach Separate Agreements with US Government to Lower Drug Prices and Support Innovation

Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.

Novartis | 22/12/2025 | By News Bureau

Novartis Breaks Ground on Flagship Manufacturing Hub in North Carolina

Novartis has officially begun construction of its flagship manufacturing hub in North Carolina, reinforcing its commitment to end-to-end production of key medicines for US patients. The project, highlighted by FDA Commissioner Marty Makary and Governor Josh Stein, underscores Novartis’ ongoing investment and growth in the US pharmaceutical sector.

Novartis | 15/12/2025 | By News Bureau |  118

Lupin Receives Tentative US FDA Nod for Siponimod Tablets, Generic to Novartis' Mayzent

Lupin has received tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Siponimod Tablets in strengths of 0.25 mg, 1 mg and 2 mg.

Novartis | 05/12/2025 | By Dineshwori |  171

Novartis to cut 550 jobs in Switzerland as it shifts focus to cell therapy and advanced biologics

Novartis announced plans to eliminate 550 jobs in Switzerland by the end of 2027 as part of a strategic shift toward cell therapy, RNA-based medicines, and other advanced biologics. The cuts will primarily affect its Stein facility, where the company is phasing out the production of pills, capsules, and sterile medicine packaging.

Novartis | 27/11/2025 | By Darshana |  200

Novartis Reports Promising Results for New Anti-Malaria Drug to Tackle Growing Resistance

Novartis’ Phase III trial of KLU156 (GanLum) met its primary endpoint, showing a 97.4 percent PCR-corrected cure rate comparable to Coartem. If approved, GanLum would mark the first major malaria treatment breakthrough in over two decades, targeting drug-resistant parasites.

Novartis | 13/11/2025 | By Dineshwori

Novartis Opens New Radioligand Therapy Plant in California under USD 23 Billion US Expansion Plan

Novartis has inaugurated its third US-based radioligand therapy (RLT) manufacturing facility in Carlsbad, California, expanding its production network to meet growing demand and maintain a 99.9 percent on-time delivery rate for patients across the western United States, Alaska, and Hawaii.

Novartis | 12/11/2025 | By Dineshwori |  169

Novartis Opens New California Plant to Boost Cancer Drug Production

Novartis has opened a new 10,000-square-foot manufacturing facility in Carlsbad, California, to produce advanced radioligand therapies (RLTs) for cancer treatment. These innovative therapies combine precision targeting with radioactive particles to attack cancer cells while minimizing damage to healthy tissue.

Novartis | 11/11/2025 | By Darshana |  167

Novartis agrees to acquire Avidity Biosciences

Novartis has announced a definitive agreement to acquire Avidity Biosciences, a move aimed at expanding its neuroscience portfolio with advanced programs targeting rare genetic neuromuscular disorders.

Novartis | 27/10/2025 | By Dineshwori |  143